Eledon Shares Rise on Fast-Track Designation for Kidney Treatment
By Katherine Hamilton
Eledon Pharmaceuticals shares rose after the company said its kidney treatment was granted fast-track designation by the Food and Drug Administration.
The stock rose 13% to $3.04 on Tuesday. Shares are up 87% this year.
Patients treated with tegoprubart in a Phase 2 trial had statistically significantly higher kidney function through 24 months compared with tacrolimus, Eledon said.
The fast-track designation is to develop tegoprubart as a prevention for rejections in kidney transplants, Eledon said. No rejections occurred in the tegoprubart arm of the trial after six months post-transplant, it added.
The FDA's designation is meant to facilitate the development and expedite the review of drugs that treat serious conditions and address unmet medical needs.
The biotechnology company said it is on track to initiate its Phase 3 trial of tegoprubart in kidney transplantation in the fourth quarter of this year. The trial is expected to enroll about 600 patients, it said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
September 22, 2026 12:21 ET (16:21 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
6 ETFs To Diversify Away From AI
The Best AI Stocks to Buy Now
United States